+ FROM THE BLOG +
OUR MOST RECENT POSTS
<p>Welcome to this weeks ETF ALPHA. Our picks have done well in the past two weeks. <span style="color: #339966;"><strong>DRN +1.5%, EDC +8%, LABU +8%. <span style="color: #333333;">and</span> SOXL +12%</strong></span>. </p> <p>I recently posted <strong>my <a href="http://thestocksdoctor.com/trading-system/">trading system</a></strong>, thus allowing you all to follow me accordingly and trade using the same system that I use.</p> <p>This week our watch list includes: DRN EDC LABU SOXL UGLD SPXL.</p>
Non-alcoholic steatohepatitis (NASH) is becoming an increasingly popular disease affecting many worldwide. This disease leads to increased liver-related mortality secondary to liver cirrhosis (fibrosis) and even hepatocellular carcinoma (liver cancer). To date, there is no known FDA approved drug therapy for this disease and generally, 15-20% of patients with NASH will require a liver transplant. Intercept Pharmaceuticals Inc. (ICPT) is expected to release news regarding their findings in the Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE trial) this week. Below, I breakdown the potential outcomes of this trial along with the likelihood that the company will succeed or fail with regards to getting FDA approval. Next, I highlight what the FDA will be looking for to provide approval and lastly, will provide my valuation of ICPT with associated risks and potential options play.
<p>Good morning and welcome to this weeks ETF ALPHA. It seems that a lot of the ETFs had a pullback last week after having three weeks of bullish run. This is great for us as it now presents with potential buying opportunity for us. I recently posted my <a href="http://thestocksdoctor.com/trading-system/">trading system</a>, thus allowing you all to follow me accordingly and trade using the same system that I use.</p> <p>This week our watch list includes EDC, DRN, LABU, SOXL</p>
Smart. Flexible. For Everyone.
+ GAIN ACCESS TO +
+ ETF ALPHA +
Weekly ETF Trading Plan
Our Weekly Exclusive ETF trades perfect for the busy professional. Trade plan provided before the start of the week so you can set it and forget it. Ideal for the swing-traders and long-term investors.
+ MORNING ROUNDS +
Stock Market Insight
Daily Stock Market News – featuring a Daily Stock Pick. Ideal for day-trading, swing-traders, and long-term investing.
+ STOCKS RESEARCH +
Exclusive Research into Selected Stocks
We provide our readers with Extensive Research into selected stocks. Ideal for the swing-traders and long-term investors.
+ ABOUT ME +
I am a recent graduate from Dalhousie Medical School. Prior to enrolling in medical school, I completed my Bachelor of Science with Honours in 2010 in Biochemistry. I then obtained my PhD at Dalhousie University in Pharmacology in 2014, with a focus around regenerative medicine and stem cell transplantation for myocardial regeneration post-myocardial infarction. I have been published in numerous high impact journals and also co-authored a few books.
My passion for medicine, technology, and the financial markets lead to the foundation of The Stocks Doctor. I want to create an environment where those with or without any formal education in the financial markets, such as scientists and medical professionals, can work to become better traders and investors.
JOIN ME, SO TOGETHER WE CAN BECOME BETTER TRADERS AND INVESTORS, AND INVEST IN PROJECTS AND COMPANIES THAT CAN HELP SHAPE AND FORM OUR FUTURE FOR THE BETTER.
Dr. Tiam Feridooni, MD, PhD, BSc
+ JOIN ME NOW +
ON THE JOURNEY TO BECOME A BETTER TRADER AND AN INVESTOR
*Individual Results may vary, and testimonials are not claimed to represent typical results. All testimonials are made by real clients, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. Thus, the experiences that we share from other people may not reflect the typical users’ experience.